Tokyo, Japan - August 1, 2022 - Medical and Biological Laboratories Co., Ltd. (President & CEO: Kimimasa Yamada, “MBL”), a JSR Life Sciences Company, announced that MEBGEN™ BRAF Kit, an in vitro diagnostic reagent, was approved for detection of BRAF gene mutations (V600E or V600K) by the Ministry of Health, Labour and Welfare (MHLW) for production and marketing in Japan on July 7, 2022.
MEBGEN™ BRAF Kit was developed as a companion diagnostic for multiple anti-cancer agents in melanoma. The MEBGEN BRAF Kit is expected to be an important clinical diagnostic in guiding personalized medicine for patients with melanoma.
Purpose of use: Detection of BRAF gene mutations (V600E or V600K) in DNA extracted from cancer tissue
Head Quarters: SUMITOMO FUDOSAN SHIBADAIMON NICHOME BLDG. 2-11-8 Shibadaimon, Minato-ku, Tokyo 105-0012 Japan
Contact form: https://www.mblbio.com/e/contact/
MBL was established in 1969 as the first antibody manufacturer in Japan, and researches, develops, manufactures, and sells reagents of in vitro diagnostics and reagents for basic research. MBL has now expanded its business not only to the immunological field but also to the field of genetic diagnosis. In the field of oncology, MBL is contributing to personalized medicine by developing companion diagnostics. For more information, please visit https://www.mblbio.com/cdx/